- Recce Pharmaceuticals (RCE) has secured a patent from the European regulator covering two of its synthetic anti-infective formulations
- This is the second time Recce has granted a patent in the Patent Family 3 group after a patent previously granted by Japan’s regulator
- The new patent will cover marketing and manufacturing activities associated with the company’s Recce 327 and Recce 529 drug candidates until February 2037
- These drugs aim to stop the rapid spread of bacteria and viruses, respectively
- The new E.U. patent also covers Recces’s use of the candidates on viruses like COVID-19, HIV and Ross River Virus
- Shares in RCE ended the day at 96.5 cents per share
